New drug aims to stop aggressive nose cancer from coming back
Disease control
Not yet recruiting
This phase 2 trial tests whether the drug becotatug vedotin can prevent cancer from returning in 140 patients with high-risk nasopharyngeal carcinoma who have completed standard chemo-radiation. Participants are randomly assigned to receive the drug or standard care. The main goa…
Phase: PHASE2 • Sponsor: Kai Hu • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC